209 related articles for article (PubMed ID: 27299795)
1. Benign and Malignant Brenner Tumors Show an Absence of TERT Promoter Mutations That Are Commonly Present in Urothelial Carcinoma.
Khani F; Diolombi ML; Khattar P; Huang W; Fallon JT; Epstein JI; Zhong M
Am J Surg Pathol; 2016 Sep; 40(9):1291-5. PubMed ID: 27299795
[TBL] [Abstract][Full Text] [Related]
2. Mutational profiles of Brenner tumors show distinctive features uncoupling urothelial carcinomas and ovarian carcinoma with transitional cell histology.
Pfarr N; Darb-Esfahani S; Leichsenring J; Taube E; Boxberg M; Braicu I; Jesinghaus M; Penzel R; Endris V; Noske A; Weichert W; Schirmacher P; Denkert C; Stenzinger A
Genes Chromosomes Cancer; 2017 Oct; 56(10):758-766. PubMed ID: 28639280
[TBL] [Abstract][Full Text] [Related]
3. Recurrent TERT promoter mutations in urothelial carcinoma and potential clinical applications.
Kurtis B; Zhuge J; Ojaimi C; Ye F; Cai D; Zhang D; Fallon JT; Zhong M
Ann Diagn Pathol; 2016 Apr; 21():7-11. PubMed ID: 27040924
[TBL] [Abstract][Full Text] [Related]
4. Recurrent urothelial carcinoma-like FGFR3 genomic alterations in malignant Brenner tumors of the ovary.
Lin DI; Killian JK; Venstrom JM; Ramkissoon SH; Ross JS; Elvin JA
Mod Pathol; 2021 May; 34(5):983-993. PubMed ID: 33077920
[TBL] [Abstract][Full Text] [Related]
5. Flow cytometric DNA analysis of ovarian Brenner tumors and transitional cell carcinomas.
Martin AR; Kotylo PK; Kennedy JC; Fineberg NS; Roth LM
Int J Gynecol Pathol; 1992 Jul; 11(3):188-96. PubMed ID: 1399228
[TBL] [Abstract][Full Text] [Related]
6. Targeted sequencing of plasmacytoid urothelial carcinoma reveals frequent TERT promoter mutations.
Palsgrove DN; Taheri D; Springer SU; Cowan M; Guner G; Mendoza Rodriguez MA; Rodriguez Pena MDC; Wang Y; Kinde I; Ricardo BFP; Cunha I; Fujita K; Ertoy D; Kinzler KW; Bivalacqua TJ; Papadopoulos N; Vogelstein B; Netto GJ
Hum Pathol; 2019 Mar; 85():1-9. PubMed ID: 30447301
[TBL] [Abstract][Full Text] [Related]
7. Transitional cell tumors of the ovary: a comparative clinicopathologic, immunohistochemical, and molecular genetic analysis of Brenner tumors and transitional cell carcinomas.
Cuatrecasas M; Catasus L; Palacios J; Prat J
Am J Surg Pathol; 2009 Apr; 33(4):556-67. PubMed ID: 19033864
[TBL] [Abstract][Full Text] [Related]
8. Immunoprofile of ovarian tumors with putative transitional cell (urothelial) differentiation using novel urothelial markers: histogenetic and diagnostic implications.
Logani S; Oliva E; Amin MB; Folpe AL; Cohen C; Young RH
Am J Surg Pathol; 2003 Nov; 27(11):1434-41. PubMed ID: 14576476
[TBL] [Abstract][Full Text] [Related]
9. High prevalence of TERT promoter mutations in micropapillary urothelial carcinoma.
Nguyen D; Taheri D; Springer S; Cowan M; Guner G; Mendoza Rodriguez MA; Wang Y; Kinde I; VandenBussche CJ; Olson MT; Ricardo BF; Cunha I; Fujita K; Ertoy D; Kinzler KW; Bivalacqua TJ; Papadopoulos N; Vogelstein B; Netto GJ
Virchows Arch; 2016 Oct; 469(4):427-34. PubMed ID: 27520411
[TBL] [Abstract][Full Text] [Related]
10. Telomerase reverse transcriptase promoter mutations in glandular lesions of the urinary bladder.
Vail E; Zheng X; Zhou M; Yang X; Fallon JT; Epstein JI; Zhong M
Ann Diagn Pathol; 2015 Oct; 19(5):301-5. PubMed ID: 26239299
[TBL] [Abstract][Full Text] [Related]
11. Small-cell Carcinomas of the Urinary Bladder and Prostate: TERT Promoter Mutation Status Differentiates Sites of Malignancy and Provides Evidence of Common Clonality Between Small-cell Carcinoma of the Urinary Bladder and Urothelial Carcinoma.
Priemer DS; Wang M; Zhang S; Lopez-Beltran A; Kouba E; Montironi R; Davidson DD; MacLennan GT; Wang L; Osunkoya AO; Deng Y; Emerson RE; Cheng L
Eur Urol Focus; 2018 Dec; 4(6):880-888. PubMed ID: 28753872
[TBL] [Abstract][Full Text] [Related]
12. High frequency of TERT promoter mutation in small cell carcinoma of bladder, but not in small cell carcinoma of other origins.
Zheng X; Zhuge J; Bezerra SM; Faraj SF; Munari E; Fallon JT; Yang XJ; Argani P; Netto GJ; Zhong M
J Hematol Oncol; 2014 Jul; 7():47. PubMed ID: 25042800
[TBL] [Abstract][Full Text] [Related]
13. PAX8 expression and TERT promoter mutations in the nested variant of urothelial carcinoma: a clinicopathologic study with immunohistochemical and molecular correlates.
Taylor AS; McKenney JK; Osunkoya AO; Chan MP; Al-Ahmadie HA; Spratt DE; Fullen DR; Chinnaiyan AM; Brown NA; Mehra R
Mod Pathol; 2020 Jun; 33(6):1165-1171. PubMed ID: 31932679
[TBL] [Abstract][Full Text] [Related]
14. Brenner tumors but not transitional cell carcinomas of the ovary show urothelial differentiation: immunohistochemical staining of urothelial markers, including cytokeratins and uroplakins.
Riedel I; Czernobilsky B; Lifschitz-Mercer B; Roth LM; Wu XR; Sun TT; Moll R
Virchows Arch; 2001 Feb; 438(2):181-91. PubMed ID: 11253121
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Value of TERT Alterations, Mutational and Copy Number Alterations Burden in Urothelial Carcinoma.
Isharwal S; Audenet F; Drill E; Pietzak EJ; Iyer G; Ostrovnaya I; Cha E; Donahue T; Arcila M; Jayakumaran G; Berger MF; Rosenberg JE; Bajorin DF; Coleman J; Dalbagni G; Reuter VE; Bochner BH; Solit DB; Al-Ahmadie HA
Eur Urol Focus; 2019 Mar; 5(2):201-204. PubMed ID: 28802642
[TBL] [Abstract][Full Text] [Related]
16. Molecular Genetic Analysis of Ovarian Brenner Tumors and Associated Mucinous Epithelial Neoplasms: High Variant Concordance and Identification of Mutually Exclusive RAS Driver Mutations and MYC Amplification.
Tafe LJ; Muller KE; Ananda G; Mitchell T; Spotlow V; Patterson SE; Tsongalis GJ; Mockus SM
Am J Pathol; 2016 Mar; 186(3):671-7. PubMed ID: 26797085
[TBL] [Abstract][Full Text] [Related]
17. Expression of the urothelial differentiation markers GATA3 and placental S100 (S100P) in female genital tract transitional cell proliferations.
Esheba GE; Longacre TA; Atkins KA; Higgins JP
Am J Surg Pathol; 2009 Mar; 33(3):347-53. PubMed ID: 19092634
[TBL] [Abstract][Full Text] [Related]
18. Malignant Brenner tumor and transitional cell carcinoma of the ovary: a comparison.
Austin RM; Norris HJ
Int J Gynecol Pathol; 1987; 6(1):29-39. PubMed ID: 3570630
[TBL] [Abstract][Full Text] [Related]
19. Telomerase reverse transcriptase (TERT) promoter mutations in primary adenocarcinoma of bladder and urothelial carcinoma with glandular differentiation: pathogenesis and diagnostic implications.
Cheng L; Lopez-Beltran A; Wang M; Montironi R; Kaimakliotis HZ; Zhang S
Mod Pathol; 2021 Jul; 34(7):1384-1391. PubMed ID: 33674765
[TBL] [Abstract][Full Text] [Related]
20. The pathogenesis of atypical proliferative Brenner tumor: an immunohistochemical and molecular genetic analysis.
Kuhn E; Ayhan A; Shih IeM; Seidman JD; Kurman RJ
Mod Pathol; 2014 Feb; 27(2):231-7. PubMed ID: 23887305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
